New Patient Registry Will Track Safety of Pradaxa, Other Antithrombolic Treatments
Boehringer Ingelheim, maker of the increasingly popular anticoagulant drug Pradaxa, has announced that it will establish a new patient registry which will allow the company to track the safety of Pradaxa for patients suffering from a heart rhythm condition known as atrial fibrillation (AF). The GLORIA(TM)-AF Registry is expected to